Identification of a ubiquitin-binding domain protein, CD2AP, in predicting the prognosis and treatment of lung adenocarcinoma
Our study identifies <i>CD2AP</i> as a key oncoprotein in LUAD. Our findings suggest that targeting <i>CD2AP</i> represents a promising therapeutic strategy for patients with LUAD. Integrating <i>CD2AP</i> assessment into clinical practice may enhance personalised treatment planning and prognostic evaluation for patients with LUAD.
Authors
- Qinjin Dai (ORCID: https://orcid.org/0000-0002-0504-5668)
- Mingfeng He
- Zhixiang Bo
- Li Li (ORCID: https://orcid.org/0000-0003-2294-9842)
- Jin Huang (ORCID: https://orcid.org/0000-0002-8154-942X)
- Ying Ye
- Jishan Yin
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- The Affiliated Yongchuan Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-12-04
- DOI
- https://doi.org/10.3389/fimmu.2025.1726531
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 0.00